FEW PATHOLOGISTS OR CLINICAL laboratory directors would argue against revising the current Medicare payment policies for molecular and genetic tests. A bill proposed in Congress would do just that. The process now in use by Medicare Administrative Contractors (MACs) is inefficient and opaque, according to pathologists and lab executives. The result is not many clinical […]
- "MolDx Test Update"
House Bill Introduced to Address Rate-Setting for Molecular Tests
HHS would need to justify payment rates for tests and provide a reasonable period for reconsideration
- By Robert Michel
- > From the Volume XX No. 10 - July 29, 2013 Issue
